Ally Bridge Group (Ny) LLC Trevi Therapeutics, Inc. Transaction History
Ally Bridge Group (Ny) LLC
- $141 Million
- Q3 2024
A detailed history of Ally Bridge Group (Ny) LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Ally Bridge Group (Ny) LLC holds 1,322,800 shares of TRVI stock, worth $3.64 Million. This represents 3.14% of its overall portfolio holdings.
Number of Shares
1,322,800
Previous 1,474,926
10.31%
Holding current value
$3.64 Million
Previous $4.4 Million
0.52%
% of portfolio
3.14%
Previous 4.12%
Shares
2 transactions
Others Institutions Holding TRVI
# of Institutions
94Shares Held
57.1MCall Options Held
136KPut Options Held
5.4K-
Nea Management Company, LLC Timonium, MD11.4MShares$31.3 Million2.9% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.38MShares$20.3 Million1.33% of portfolio
-
Rubric Capital Management LP New York, NY5.03MShares$13.8 Million0.47% of portfolio
-
Viking Global Investors LP4.4MShares$12.1 Million0.06% of portfolio
-
Vr Adviser, LLC New York, NY3.42MShares$9.41 Million1.18% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $160M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...